24-Hour Crisis Hotline: (877)SAFEGBC or (877)723-3422 Mental Health & Substance Abuse Issues

6502 Nursery Drive, Suite 100
Victoria, TX 77904
(361)575-0611
(800)421-8825

Diabetes
Resources
Basic InformationLatest News
Insulin Doesn't Prevent Diabetes in Relatives of T1DM PatientsInsulin Pill May Delay Type 1 Diabetes in SomeHealth Tip: Diabetes Affects Women DifferentlySevere Psoriasis May Make Diabetes Increasingly LikelySpinal Cord Stimulation May Reduce Neuropathic PainBrain Glucose Responses Diminish With Diabetes, ObesityRisk of Falls Up With Mild, Moderate Diabetic RetinopathyFirst-Line Metformin Use for DM Up; Sulfonylurea Use DownPoor Prognosis for Diabetic Foot SoresER- Breast CA Risk Up for African-Americans With T2DMIn 2007-2014, Glycemic Control Plateaued in Diabetes PatientsDiabetes May Be Driving High Rates of Breast Cancer in Black WomenLeisure Time Exercise Linked to Reduced Mortality in T1DMAHA: Sudden Cardiac Death Risk Up for Young With DiabetesYounger People With Diabetes Have 7 Times Greater Risk of Sudden Heart DeathRisk of End-Stage Renal Disease Low With Type 1 DiabetesDrop in Incidence of End-Stage Renal Disease Due to DiabetesHealth Tip: Choosing Smarter FoodsLifestyle Changes Successfully Reduce Incidence of DiabetesNovel Method Developed for Estimating Prevalence of DiabetesNovel Artificial Pancreas Cuts HbA1c, Hypoglycemia in T1DMKidney Failure Declining Among U.S. Diabetics: CDCACE Inhibitor, Statin No Benefit for T1DM, High Albumin ExcretionMagnesium, T2DM Link Seen in Poor-Carbohydrate-Quality DietRetinal Sensitivity Linked to Cognitive Status in T2DMKidney Damage Seen in Most Patients With Long-Lasting T1DArterial Stiffness Linked to Incidence of DiabetesUndiagnosed Diabetes Accounts for Small Portion of DiabetesNew Clinical Practice Guideline for Management of T2DMDiabetes Tied to Worse Outcomes in Heart Failure PatientsStatins May Raise Odds of T2DM in Those at High RiskFinancial Incentives Up Teen Glucose Monitoring AdherenceFewer Diabetes Cases Being MissedSudden Death Most Common CV Death in T2DM/ASCVDDiabetes Ups Risk of MACE in Acute Coronary SyndromesLifestyle, Metformin Interventions Have Variable EffectsHealth Tip: Best Grains And Starchy Veggies for DiabeticsGlycemic Control Up With Oral Semaglutide in Type 2 DiabetesCommercial Weight Management Program May Help Prevent T2DDiabetes Pill Might Replace Injection to Control Blood SugarNew Screening Tool Can Identify Diabetic RetinopathyRisk Conferred by T2D Modified by HbA1c in Heart FailureNo Causal Link Between Plasma Lipids, Diabetic RetinopathyBetter Glycemic Control With Insulin Pump for Youth With T1DPump May Beat Shots for Type 1 DiabetesWhere There's Type 1 Diabetes, Celiac Disease May FollowFlu Shot Key for People With DiabetesMaking Halloween a Treat for Kids With DiabetesPay for Performance Cuts Mortality in Diabetes PatientsAddition of DPP4i to AGI Reduces HbA1c in T2DM
Links
Related Topics

Medical Disorders

DAPT Cessation Patterns Vary With Diabetes Status After PCI


HealthDay News
Updated: Mar 29th 2017

new article illustration

WEDNESDAY, March 29, 2017 (HealthDay News) -- For patients undergoing dual antiplatelet therapy (DAPT) after percutaneous coronary intervention with a drug-eluting stent (DES), DAPT cessation is significantly lower in patients with diabetes mellitus (DM), according to a study published in the March 27 issue of JACC: Cardiovascular Interventions.

Michela Faggioni, M.D., from Mount Sinai Medical Center in New York City, and colleagues identified 1,430 patients with DM and 2,777 without DM treated with DES after percutaneous coronary intervention. The authors examined temporal variability in the risk of major adverse cardiovascular events (MACE) in relation to DAPT cessation patterns.

The researchers found that DM correlated with increased risk of thrombotic events during two-year follow-up, but with a similar risk of bleeding. Patients with versus without DM had significantly lower cumulative incidence of DAPT cessation (50.1 versus 55.4 percent; P < 0.01), which was mainly driven by less frequent physician-guided discontinuation beyond one year. The groups had similar two-year rates of interruption and disruption. Interruption or discontinuation of DAPT under physician guidance correlated with no change in the risk of MACE compared to DM patients on uninterrupted DAPT. Compared with uninterrupted DAPT, disruption was associated with increased risk of MACE, regardless of the diabetic status.

"DAPT cessation patterns vary according to diabetic status, with less frequent physician-guided discontinuation among patients with DM," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.

Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)